The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract

Digestion

Volumn 79, Issue SUPPL. 1, 2009, Pages 33-39

  Oki, Eiji ^a   Zhao, Yan ^a   Yoshida, Rintaro ^a   Egashira, Akinori ^a   Ohgaki, Kippei ^a   Morita, Masaru ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Colon cancer; Esophageal cancer; Gastric cancer; p53; Spectrum

Indexed keywords

PROTEIN P53;

COLON CANCER; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GENE; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; INTESTINE CANCER; P53 GENE; PRIORITY JOURNAL; STOMACH CANCER; UPPER GASTROINTESTINAL TRACT;

AGED; CARCINOMA; DNA, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 58549097657     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167864     Document Type: Conference Paper

References (36)

1. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P: New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999;431:199-209.
2. Giaccia AJ, Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973-2983.
3. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-749.
4. Sun XF, Carstensen JM, Zhang H, et al: Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369-1373.
5. Bosari S, Viale G, Bossi P, et al: Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994;86:681-687.
6. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A: TP53 and gastric carcinoma: a review. Hum Mutat 2003;21:258-270.
7. Iacopetta B: TP53 mutation in colorectal cancer. Hum Mutat 2003;21:271-276.
8. Oki E, Tokunaga E, Nakamura T, et al: Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Lett 2005;227:33-38.
9. Egashira A, Morita M, Kakeji Y, et al: p53 Gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries. Cancer Sci 2007;98:1152-1156.
10. Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS: p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994;54:4342-4346.
11. Shi ST, Yang GY, Wang LD, et al: Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999;20:591-597.
12. Sepehr A, Taniere P, Martel-Planche G, et al: Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran. Oncogene 2001;20:7368-7374.
13. Hu N, Huang J, Emmert-Buck MR, et al: Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. Clin Cancer Res 2001;7:883-891.
14. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR: DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992;89:3030-3034.
15. Wink DA, Kasprzak KS, Maragos CM, et al: DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991;254:1001-1003.
16. Sugimura T, Tanaka N, Kawachi T, Kogure K, Fujimura S: Production of stomach cancer in dogs by N-methyl-N′-nitro-N-nitrosoguanidine. Gann 1971;62:67.
17. Matsumoto Y, Marusawa H, Kinoshita K, et al: Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007;13:470-476.
18. Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC: Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat Immunol 2003;4:452-456.
19. Yoshikawa K, Okazaki IM, Eto T, et al: AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 2002;296:2033-2036.
20. Soussi T, Dehouche K, Beroud C: p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-113.
21. Beroud C, Soussi T: The UMD-p53 database: new mutations and analysis tools. Hum Mutat 2003;21:176-181.
22. Soong R, Powell B, Elsaleh H, et al: Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-2060.
23. Jernvall P, Makinen M, Karttunen T, Makela J, Vihko P: Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers. Int J Cancer 1997;74:97-101.
24. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E: TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998;4:203-210.
25. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE: p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-2223.
26. Kanamoto A, Kato H, Tachimori Y, et al: No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 1999;72:94-98.
27. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.
28. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ: Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996;32A:215-220.
29. Kim YW, Lee S, Park JH, Yoon TY, Park YK, Yang MH: An immunohistochemical study of the expression of p53 protein in colon cancer. J Korean Med Sci 1995;10:176-182.
30. Soong R, Grieu F, Robbins P, et al: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 1997;3:1405-1411.
31. Manne U, Weiss HL, Myers RB, et al: Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer 1998;83:2456-2467.
32. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-250.
33. Hardwick RH, Barham CP, Ozua P, et al: Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997;23:30-35.
34. Lam KY, Law S, Tung PH, Wong J: Esophageal small cell carcinomas: clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis. Arch Pathol Lab Med 2000;124:228-233.
35. Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y, Sugimachi K: Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology 2002;63:353-361.
36. Maehara Y, Okuyama T, Kakeji Y, Endo K, Yamamoto M, Sugimachi K: A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. Br J Cancer 1995;71:999-1002.